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Therapeutic failure of benznidazole (BZ) is widely documented in Chagas disease and has been primarily as-
sociated with variations in the drug susceptibility of Trypanosoma cruzi strains. In humans, therapeutic success has 
been assessed by the negativation of anti-T. cruzi antibodies, a process that may take up to 10 years. A protocol for 
early screening of the drug resistance of infective strains would be valuable for orienting physicians towards alter-
native therapies, with a combination of existing drugs or new anti-T. cruzi agents. We developed a procedure that 
couples the isolation of parasites by haemoculture with quantification of BZ susceptibility in the resultant epimas-
tigote forms. BZ activity was standardized with reference strains, which showed IC50 to BZ between 7.6-32 µM. The 
assay was then applied to isolates from seven chronic patients prior to administration of BZ therapy. The IC50 of the 
strains varied from 15.6 ± 3-51.4 ± 1 µM. Comparison of BZ susceptibility of the pre-treatment isolates of patients 
considered cured by several criteria and of non-cured patients indicates that the assay does not predict therapeutic 
outcome. A two-fold increase in BZ resistance in the post-treatment isolates of two patients was verified. Based on 
the profile of nine microsatellite loci, sub-population selection in non-cured patients was ruled out. 
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Human Chagas disease is a neglected illness that af-
fects 10-12 million individuals from nearly all countries 
of Latin America. Due to migrations, Chagas disease 
cases have been reported throughout the world. In Latin 
America, the transmission of the protozoan Trypano-
soma cruzi, the causative agent of Chagas disease, has 
been steadily reduced through a series of multinational 
initiatives aimed at the elimination of domestic vectors 
in extensive areas, as well as screening of blood donors 
for T. cruzi infection (Schofield et al. 2006). Neverthe-
less, serious challenges remain for complete elimination 
of transmission, including the peculiar epidemiology of 
Chagas disease, limitations in the available specific che-
motherapy and insufficient treatment coverage for indi-
viduals currently infected.
Chagas disease progresses through two successive 
stages: the acute phase, with patent parasitemia, and the 
chronic phase, characterized by sub-patent parasitemia 
and scarce tissue parasitism. The majority of chronic 
individuals are asymptomatic (indeterminate form), 
whereas up to 30-40% of patients develop chronic cardi-
omyopathy or gastrointestinal disorders. While Chagas 
disease pathology is poorly understood, accumulating 
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evidence indicates that parasite persistence within the 
target organs, in concert with an unbalanced immune re-
sponse, plays a central role in the development of pathol-
ogy in both the acute and chronic phases (WHO 2002). 
Accordingly, the prevailing opinion is that Chagas dis-
ease should be treated with anti-parasitic compounds 
(Gontijo et al. 1999, WHO 2002).
Two nitro-heterocyclic compounds have been used 
for the specific treatment of T. cruzi infection: nifurtimox 
(NF) (launched by Bayer in 1967, Lampit®) and benznida-
zole (BZ) (launched by Roche in 1972, Rochagan® and 
Radanil®) (Coura & de Castro 2002). In patients, the two 
compounds require long courses of treatment and exhibit 
variable efficacy and undesirable side effects. Numerous 
clinical trials have reported up to 80% parasitological 
cure in the acute phase (Bahia-Oliveira et al. 2000) and 
60-70% cure in recently developed chronic phase dis-
ease in children up to 14 years of age (de Andrade et al. 
1996, Sosa-Estani et al. 1998, 2009, Yun et al. 2009). The 
major limitation on the use of both BZ and NF is low 
anti-parasitic activity in the chronic phase, with only 
5-20% of patients considered cured, as assessed by 20 
years or more follow-up (Cançado 2002, Dias 2006). On 
the other hand, BZ treatment in this phase yields a better 
prognosis for the clinical evolution of chagasic cardio-
myopathies (Viotti et al. 2006, Sosa-Estani et al. 2009).
One of the priorities in Chagas disease research 
should be to produce new drugs, providing a shorter 
treatment course with fewer side effects and to devise 
paediatric formulations for these drugs. Ergosterol bio-
synthesis inhibitors are currently the most advanced can-
didates for new anti-T. cruzi agents, as they have been 
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shown to have curative activity in chronic infections 
in mice and to be active against NF and BZ-resistant T. 
cruzi strains (Urbina 2009). Ergosterol biosynthesis in-
hibitors are poised for clinical trials in Chagas disease 
patients in the short term. An expert committee has also 
recommended that combination therapy using existing 
and/or new drugs should be employed to avoid drug re-
sistance (Report of the Disease Reference Group of TDR 
on Chagas disease, Leishmaniasis and Human African 
Trypanosomiasis, personal communication).
The reasons for the marked differences in efficacy 
for the nitroderivatives in the acute and chronic stages 
of Chagas disease are not known (Cançado 2002). In ad-
dition, geographic differences in therapeutic outcome 
were reported, indicating that indices of cure can be 
detected earlier in Central America and northern coun-
tries of South America than in Southern Cone countries 
(Rassi & Luquetti 1992, Yun et al. 2009). Such differ-
ences may be explained by a number of reasons. One 
primary explanation may be the presence of different 
parasite lineages in different geographic regions, with T. 
cruzi I predominating in Central America and T. cruzi II 
in South America (Carranza et al. 2009 and cited refer-
ences). In fact, variations in drug susceptibility among 
T. cruzi strains have been documented widely in in vitro 
and in vivo studies (Filardi & Brener 1987, Murta et al. 
1998, Toledo et al. 2003, Villarreal et al. 2004). Another 
factor to consider is the time between vector control ac-
tivity and drug treatment because cases (mostly asymp-
tomatic) treated closer to the time of the acute phase of 
the disease might account for more rapid cure. Finally, 
differences in immune response among populations may 
also play a role (Yun et al. 2009).
A serious problem related to the treatment of Chagas 
disease is the unsatisfactory evaluation of therapy effica-
cy and diagnosis of cure. Currently, successful treatment 
is assessed by the disappearance of anti-T. cruzi antibod-
ies (seroconversion), while therapeutic failure is assigned 
by the persistence of the parasite. Regrettably, serological 
markers may take up to 10 years to disappear and para-
sitological tests by haemoculture or xenodiagnosis have 
limited sensitivity (Gontijo et al. 1999). An upcoming 
polymerase chain reaction (PCR)-based assay is a prom-
ising tool in the evaluation of parasitological cure, but 
it still presents limitations (Britto 2009). Therefore, the 
lack of a better marker for indicating parasitological cure 
is a major impediment to advances in the treatment and 
development of more effective drugs for Chagas disease. 
Contrary to bacterial infections, in which laboratory 
assays to measure antibiotic susceptibility are well es-
tablished, a procedure to evaluate BZ susceptibility of T. 
cruzi parasites isolated from humans has not been stan-
dardized. The early diagnosis of drug resistance would 
improve the clinical management of Chagas disease, 
dictating alternative therapies with a combination of ex-
isting drugs or new anti-T. cruzi agents. In this study, we 
have developed a methodology to quantify BZ suscepti-
bility in haemoculture-derived isolates from patients in 
the chronic phase of Chagas disease. The procedure was 
applied to parasites obtained before and after BZ treat-
ment. Comparison of the in vitro BZ resistance of the 
pre-treatment parasites from patients considered cured 
and from those experiencing therapeutic failure showed 
no correlation with therapeutic outcome. 
PATIENTS, MATERIALS AND METHODS
Parasite isolates and cultivation - Human isolates 
were obtained by haemoculture as described by Chiari 
et al. (1989) with some modifications. Briefly, 30 mL 
venous blood was collected in heparinized tubes and 
red blood cells were separated from the plasma by 
centrifugation (300 g for 10 min, 4ºC). The plasma su-
pernatant was centrifuged (900 g for 20 min, 4ºC) and 
3 mL liver infusion-tryptose (LIT)-10% foetal calf se-
rum (FCS) medium was added to the pellet. The packed 
red blood cells were further washed and resuspended in 
6 mL LIT-FCS. The samples were pooled, distributed 
into plastic tubes (Falcon) containing 3 mL LIT-FCS 
each and maintained at 28ºC. In order to minimize 
parasite selection, LIT-FCS medium was added ev-
ery two days to each culture for a maximum of eight 
weeks. Parasites were cryopreserved in liquid nitrogen. 
The characteristics of T. cruzi laboratory strains em-
ployed in this study are summarized in Table I. The 
recently proposed nomenclature for the strains is used, 
where discrete typing units (DTU) are defined as sets 
of stocks that are genetically more related to each oth-
er than to any other stock and that are identifiable by 
common genetic, molecular or immunological markers 
(Zingales et al. 2009).
Molecular typing of patient isolates - For DNA ex-
traction, cryopreserved stocks were thawed and cultured 
in LIT-FCS medium. Epimastigotes were washed three 
times in phosphate-buffered saline by centrifugation 
(2,000 g for 15 min, 4ºC). Total parasite DNA was ob-
tained as described (Macedo et al. 1992). T. cruzi geno-
typing was performed by amplifying nine microsatellite 
loci: SCLE10, SCLE11, MCLE01, MCLF10 and MCLG10 
(Oliveira et al. 1998) and TcTAT20, TcAAT8, TcATT14 
and TcAAAT6 (Valadares et al. 2007). Amplification of 
microsatellites by PCR was achieved as previously de-
scribed (Oliveira et al. 1998, Valadares et al. 2007). The 
microsatellite allele sizes were determined using the Al-
lelelocator software (GE Healthcare) after running 1-3 µL 
of PCR fluorescent amplicons in a 6% denaturing poly-
acrylamide gel on an ALF sequencer (GE Healthcare, 
Milwaukee, Wisconsin, USA) in comparison to standard 
size DNA fragments of 50-500 bp.
Patients and treatment scheme - Since 1997, one of 
us (EDG), in conjunction with researchers of the Clin-
ics Hospital of the Federal University of Minas Gerais 
(UFMG), has been conducting a prospective study to 
test the hypothesis that BZ treatment can impact the 
evolution of the disease, preventing or retarding the de-
velopment of defined clinical forms. Patients enrolled in 
the present study were recruited in the city of Belo Hori-
zonte, MG, and were randomly assigned BZ (5 mg/kg 
daily, distributed in 2 oral intakes, for 60 days). Further 
details on the prospective study will be published else-
where. The study protocol was ethically and technically 
reviewed and approved by the Ethical Committee of 
UFMG. Signed informed consent was obtained from the 
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participants. Two conventional serological tests (indirect 
immunofluorescence and enzyme linked immunosor-
bent assay), antibody-dependent complement-mediated 
lysis, haemoculture, PCR targeted to kDNA in blood 
samples (Galvão et al. 1993, Meira et al. 2002) and clini-
cal evaluations (electrocardiograms, echocardiograms 
and chest X-rays) were performed before treatment and 
at least biannually after treatment. In the present study, 
only seven patients of the original cohort were included. 
Treatment was started after haemocultures produced 
positive scores. All the patients completed treatment. 
During follow-up, individuals lived in an urban area and 
did not travel to endemic areas. The characteristics of 
the patients are summarized in Table II.
Assay to evaluate BZ susceptibility - The assay was 
performed in 24-well, flat-bottom tissue culture plates 
(Falcon) in 1 mL LIT-FCS medium. Different amounts 
of BZ from a 50 mM stock solution in dimethyl sulfoxide 
(DMSO) were added to each well. Exponentially grow-
ing epimastigotes (107 parasites/mL) were incubated 
with the compound for 72 h at 28ºC. After this period, 
the number of living parasites was counted in a Neu-
bauer chamber. Drug activity was determined by calcu-
lating the percentage of growth inhibition in the treated 
samples against the control in the absence of BZ. Three 
independent assays with duplicates in each assay were 
performed on separate occasions. 
Statistical analysis - For calculation of IC50, corre-
sponding to the drug concentration that inhibited par-
asite growth by 50%, the data were treated with Sig-
maPlot (version 10) software, employing the sigmoidal 
equation four-parameter logistic.
TABLE I
Characteristics of Trypanosoma cruzi laboratory strains
Strain
Geographical
origin
Host 
(phase of disease/vector) DTUb
IC50 BZ (µM)
(mean ± SD)
115 Minas Gerais (BR) Human (chronic) V 7.6 ± 3.6
Berenice 62a Minas Gerais Human (chronic) II 12.8 ± 4.9
CL Brenera Rio Grande do Sul (BR) Triatoma infestans VI 13.6 ± 4.4
Ya São Paulo (BR) Human (acute) II 16.3 ± 2.0
Berenice 78 Minas Gerais Human (chronic) II 15.8 ± 3.8
B147 Minas Gerais Human (chronic) ND 25.5 ± 3.3
Colombianaa Colombia Human (chronic) I 25.4 ± 2.7
Esmeraldo cl3 Bahia (BR) Human (acute) II 26.7 ± 0.3
Silvio X10a Pará (BR) Human (acute) I 26.1 ± 2.5
VL10a Minas Gerais Human (chronic) II 27.3 ± 2.0
SC2005 Santa Catarina (BR) Human (acute) ND 32.1 ± 5.9
YuYua Minas Gerais T. infestans I 32.0 ± 0.2
a: benznidazole (BZ) susceptibility was determined in experimentally infected mice (Filardi & Brener 1987); b: discrete typing 
units (DTU) groups classified according to Zingales et al. (2009); BR: Brazil; ND: not determined; SD: standard deviation.
TABLE II
Patients’ profile
Patient’s  
code Gender
Clinical  
form
Agea
(years) Status of the haemocultures after treatmentb
3 F Indeterminate 28 (+) 6 mo
(-) 16 mo; 31 mo; 71 mo; 92 mo
7 F Indeterminate 33 (-) 7 mo; 52 mo; 66 mo; 95 mo; 102 mo
12 M Indeterminate 51 (+) 29 mo; 56 mo
(-) 18 mo; 38 mo; 42 mo
19 M Mild cardiac damage 45 (+) 22 mo; 47 mo; 67 mo; 93 mo
(-) 112 mo
22 F Indeterminate 37 (-) 7 mo; 18 mo; 35 mo; 56 mo; 72 mo; 84 mo
36 M Indeterminate 25 (-) 4 mo; 56 mo; 91 mo
50 F Indeterminate 39 (-) 6 mo; 34 mo; 63 mo
(+) 22 mo; 48 mo; 74 mo
a: patient’s age when treatment started; b: positive (+) or negative (-) haemocultures; F: female; M: male; mo: months after treatment.
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RESULTS
Standardization of the assay for screening BZ suscep-
tibility - The in vitro assay was standardized with epimas-
tigote forms, as this developmental stage is predominant 
in haemocultures obtained from infected individuals. 
The VL10 strain, classified as resistant to BZ (Filardi & 
Brener 1987), was employed in initial tests and incubated 
for 72 h with eight BZ concentrations (1.2-480 µM, serial 
dilutions 1:2) (data not shown). The IC50 value obtained 
from three separate assays with duplicates in each assay 
was 27.3 ± 2 µM (Table I). Because the stock solution 
of BZ was diluted in DMSO, we analyzed the effect of 
different concentrations of this solvent on the viability 
of VL10 epimastigotes. Final DMSO concentrations of 
0.031-4% had no significant effect on parasite growth 
(data not shown). 
To validate the assay, susceptibility to BZ was as-
sessed for 11 additional T. cruzi laboratory strains (Table 
I). The IC50 to BZ varied from 7.6 ± 3.6-32.1 ± 5.9 µM. 
The BZ susceptibility of seven of the analyzed strains 
(indicated with an “a” in Table I) had been previously 
determined in experimentally infected mice (Filardi & 
Brener 1987). According to the authors, the strains were 
classified as susceptible (cure rates > 66%), partially 
susceptible (cure rates between 33-66%) and resistant 
(cure rates < 33%). Two strains considered susceptible 
(Berenice 62 and CL) and one strain considered partial-
ly susceptible (Y) to BZ had IC50 values between 12.8 
± 4.9-16.3 ± 2 µM in our assay (Table I). Three strains 
considered resistant (Colombiana, VL10 and YuYu) had 
IC50 between 25.4 ± 2.7 and 32.0 ± 0.2 µM. These obser-
vations suggest a correlation between in vitro BZ sus-
ceptibility and the treatment outcome reported in the ex-
perimental model. A possible exception is the Silvio X10 
strain, considered susceptible to BZ (Filardi & Brener 
1987), but which showed a high IC50 in our assay (Table 
I). Interestingly, the Silvio X10 strain was found to be 
resistant to NF in the experimental model, at variance 
with the great majority of the stocks that were either sen-
sitive or resistant to both nitro-heterocyclic compounds 
(Filardi & Brener 1987). 
Based on agreement between in vivo and in vitro BZ 
activity, we divided the laboratory strains into two groups 
and calculated the mean ± standard deviation (SD) of each 
group: group 1, susceptible (n = 5; IC50 13.3 ± 4.5 µM), and 
group 2, resistant (n = 7; IC50 28 ± 4.4 µM).
To verify the stability of the BZ susceptibility phe-
notype, we determined the IC50 of two strains (115 and 
YuYu) kept for four months via weekly sub-culture in 
LIT-FCS medium. The IC50 values determined monthly 
did not show any considerable variation, falling within 
the limits of the SD (data not shown).
BZ susceptibility of T. cruzi clinical isolates - In 
haemocultures derived from 30 mL blood, a suitable 
epimastigote density for the in vitro assay was achieved 
after approximately 60 days. The test for BZ susceptibil-
ity was applied to parasites obtained from seven chronic 
patients (4 females and 3 males), between 25-51 years of 
age (Table II). Six patients presented the indeterminate 
form of Chagas disease and one patient presented mild 
cardiac damage. IC50 values ranging from 15-50 µM were 
observed for the seven isolates obtained before initiation 
of treatment (Figure, Table III). The patients were sub-
mitted to BZ therapy and, at different times after treat-
ment, haemocultures were performed and the presence 
of parasites scored (Table II). The titre of anti-T. cruzi 
antibodies, antibody-dependent complement-mediated 
lysis and PCR targeted to kDNA were also assessed 
(data to be presented elsewhere). All of the haemocul-
tures derived from patients 7, 22 and 36 were negative 
for parasites, as were the PCR assays (data not shown). 
Negativation of anti-T. cruzi antibodies in these patients 
was observed after 8.5 (patient 7), seven (patient 22) and 
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Susceptibility to benznidazole (BZ) in clinical Trypanosoma cruzi 
isolates. Susceptibility to BZ was quantified in epimastigotes derived 
from haemocultures of seven chagasic patients before chemotherapy. 
Based on the accepted criteria, three patients were considered cured. 
TABLE III
Susceptibility to benznidazole (BZ)  
of Trypanosoma cruzi human isolates
IC50 BZ (µM)
(mean ± standard deviation)
Isolatea
(code)
Before 
treatment
After treatment
(period in which the isolate was obtained)
3 31.5 ± 4.0 10.1 ± 1.8
(6 mo)
7 35.0 ± 4.1 -
12 15.6 ± 3.2 37.5 ± 7.0
 (1 mo)
19 51.4 ± 1.3 43.45 ± 3.5
(47 mo)
48.9 ± 5.0
(93 mo)
22 19.2 ± 4.1 -
36 19.4 ± 4.2 -
50 24.4 ± 7.0 55.2 ± 3.5
(48 mo)
a: the isolates are named with the same patient’s code from 
whom they derived (Table II); mo: months after treatment.
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7.6 (patient 36) years of treatment. According to these 
criteria, the patients were considered cured (Gontijo et al. 
1999). The IC50 values of the epimastigotes of these pa-
tients were 19 ± 4 µM (patients 22 and 36) and 35 ± 4 µM 
(patient 7) (Table III). The IC50 of the pre-treatment para-
sites derived from the non-cured patients 3, 12, 19 and 
50 varied from 15.6-51.4 µM (Table III). These data in-
dicate that the IC50 values determined in our assay do 
not predict the outcome of BZ treatment. It is remark-
able that the IC50 to BZ of the pre-treatment isolate of 
the non-cured patient 012 (15.6 ± 3.2 µM) is within the 
range of the IC50 values of the above-mentioned group 1 
(susceptible strains), whereas the IC50 of the parasites of 
the putatively cured patient 7 (35 ± 4.1 µM) falls into that 
of group 2 (resistant strains).
We also determined the BZ susceptibility of the epi-
mastigotes derived from post-treatment parasites from 
the four non-cured patients (Table III). Comparison of 
the pre and post-treatment IC50 was notable (Table III): 
the isolates of patient 19 had a conserved high IC50 value 
before (51.4 ± 1.3 µM) and after treatment (43.45 ± 3.5 
and 48.9 ± 5.0 µM), whereas post-treatment isolates of 
patients 12 and 50 showed a two-fold increase in resis-
tance to BZ as compared to pre-treatment isolates. On 
the other hand, the post-treatment isolate of patient 3 
showed increased susceptibility to BZ (Table III).
Molecular typing of the isolates - In Chagas disease, 
the individual may be infected with more than one para-
site population (Macedo et al. 2004). Contemplating 
the hypothesis that variation in the IC50 of the isolates 
obtained before and after treatment could be related to 
the selection of a particular parasite population, we pro-
ceeded to genotype parasites based on the analysis of 
nine polymorphic microsatellite loci containing di, tri 
and tetra-nucleotide repetition motifs (Table IV). Using 
this set of microsatellites, it was possible to differentiate 
pre-treatment parasite populations for all four evaluated 
patients. In fact, only the locus TcAAAT6 was mono-
morphic for the group of parasites under analysis. Inter-
estingly, when examining pre and post-treatment isolates 
from a given patient, we concluded that the population 
was monoclonal and identical, as indicated by the pres-
ence of only one or two different alleles per locus. Ac-
cordingly, and within the sensitivity of the microsatellite 
assay, we ruled out parasite selection or re-infection dur-
ing or after treatment.
DISCUSSION
The three stages of the T. cruzi life cycle have been 
used for in vitro drug screening. Although the intracel-
lular amastigote model is considered the most consistent 
indicator of in vivo activity, a number of tests showed 
a strong correlation between the activity of compounds 
against epimastigote cultures and their activity in mice 
(Croft 1986, Urbina 2009). Nevertheless, differences of 
several orders of magnitude of the IC50 values of epimas-
tigotes and amastigotes were reported.
Because the goal of this study was to develop a 
procedure to measure the BZ susceptibility of clini-
cal isolates with the aim of predicting the response to 
treatment, rather than correlating BZ susceptibility of 
the epimastigotes with the treatment outcome, we stan-
dardized the assay with haemoculture-derived epimas-
tigotes. We have not attempted to develop the assay us-
ing intracellular amastigotes because the process is time 
consuming and can lead to the selection of a particular 
parasite population. The amastigote model involves the 
differentiation of haemoculture-derived epimastigotes 
into metacyclic trypomastigotes in order to establish in-
fection in mammalian cell monolayers. We have made 
an effort to obtain metacyclic trypomastigotes from the 
clinical isolates in differentiation media. The differen-
tiation efficiency varied from 0-50% (data not shown) 
depending on the isolate. We have not used bloodstream 
trypomastigotes because their numbers are low in the 
chronic phase of Chagas disease.
Standardization of the assay to measure BZ suscep-
tibility was performed with T. cruzi reference strains, 
which showed IC50 between 7.6-30 µM. These values are 
TABLE IV
Genetic characterization of Trypanosoma cruzi isolates of non-cured patients obtained  
before (BT) and after (AT) benznidazole treatment
Isolate
(code)a
Allele sizes (in bp) of microsatellite loci
MCLF10 SCLE10 SCLE11 MCLG10 MCLE01 TcAAT8 TcTAT20 TcATT14 TcAAAT6
3 BT 182/182 271/275 153/157 175/183 126/134 262/277 193/214 262/262 271/275
3 AT 182/182 271/275 153/157 175/183 126/134 262/277 193/214 262/262 271/275
12 BT 182/182 273/273 151/155 181/181 126/128 262/262 190/205 262/262 271/275
12 AT 182/182 273/273 151/155 181/181 126/128 262/262 190/205 262/262 271/275
19 BT 182/182 273/291 149/157 177/177 126/138 259/277 190/193 265/265 271/275
19 ATb 182/182 273/291 149/157 177/177 126/138 259/277 190/193 265/265 271/275
50 BF 184/184 267/267 155/155 177/185 134/138 262/274 193/217 265/265 271/275
50 AT 184/184 267/267 155/155 177/185 134/138 262/274 193/217 265/265 271/275
a: see details in Table III; b: 93 months after treatment.
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of the same order of magnitude of IC50 of epimastigotes 
in stocks belonging to different DTU (Villarreal et al. 
2004). Some studies reported that DTU I isolates were 
more resistant to BZ than parasites of the other DTUs 
(Toledo et al. 2003, 2004), whereas others showed no 
correlation between in vitro drug susceptibility and T. 
cruzi groups (Murta et al. 1998, Villarreal et al. 2004). 
Our data support the latter conclusion. We observed that 
the IC50 value is a stable characteristic that is maintained 
during prolonged epimastigote sub-culturing (up to 4 
months). This observation agrees with previous reports 
showing that drug-resistant T. cruzi parasites maintain 
this phenotype after six months of sub-culturing without 
drug pressure (Nirdé et al. 1995).
The IC50 values to BZ of T. cruzi isolates derived 
from seven patients before initiation of treatment var-
ied from 15.6 ± 3.2-51.4 ± 1.3 µM. Comparison of the 
pre-treatment IC50 values of parasites from cured and 
non-cured individuals showed no correlation with thera-
peutic outcome. Because the diagnosis of cure of Cha-
gas disease is unsatisfactory, the possibility exists that 
patients considered cured are in fact still infected. On 
the other hand, this hypothesis does not invalidate the 
conclusion that the IC50 determined in vitro is not predic-
tive of therapeutic success. 
Comparison of the BZ activity in pre and post-treat-
ment isolates showed a 2-fold increase in drug resistance 
in the post-treatment parasites of two patients. At least 
two hypotheses could explain this observation: (i) the 
selection of a more resistant parasite population already 
present in the original infecting strain or (ii) the induc-
tion of resistance by the selective pressure of the drug 
during therapy. Both hypotheses find support in the lit-
erature (Nirdé et al. 1995, Veloso et al. 2001, Villarreal 
et al. 2005, Wilkinson et al. 2008). Due to the remarkable 
polymorphism of microsatellite markers, as few as four 
microsatellite loci is usually enough to differentiate any 
two T. cruzi populations, even those that are genetically 
closely related (Oliveira et al. 1998, Macedo et al. 2001). 
Based on the profile of nine microsatellite loci, we ruled 
out any parasite selection process that may have occurred 
during or after BZ treatment. On the other hand, global 
genetic analysis based on these markers does not allow 
the identification either of specific mutations or of the 
amplification of genes which could promote increased 
resistance to BZ. Microsatellite markers also excluded 
sub-population selection of the post-treatment isolate 
that displayed increased BZ susceptibility. Variations in 
the activity of the drug in parasites recovered after treat-
ment deserve future investigation. 
In the present study, our conclusion that this in vitro 
assay does not allow the prediction of therapeutic out-
come is intriguing and challenging. The most obvious 
explanation would be that the epimastigote is not the 
infective stage and its susceptibility to BZ does not re-
flect the susceptibility of other stages (trypomastigotes 
and amastigotes) encountered in the human host. On 
the other hand, our data support the proposition that 
therapeutic success seems to depend on the interplay 
among parasite susceptibility to the trypanocidal drug, 
drug access and accumulation into different environ-
ments (plasma levels and also targeted tissues) and the 
host immune response. These parameters warrant more 
in-depth investigation for both the understanding of BZ 
trypanocidal activity and the rational development of 
new anti-Chagas disease compounds.
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